EMPLOYMENT AGREEMENT For MARK WIGGINSEmployment Agreement • February 25th, 2021 • Tracon Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • California
This Employment Agreement (the “Agreement”) is made and entered into effective as of January 27, 2021 (the “Effective Date”), by and between TRACON Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Mark Wiggins (the “Executive”). The Company and Executive are hereinafter collectively referred to as the “Parties”, and individually referred to as a “Party”. From and following the Effective Date, this Agreement shall replace and supersede that certain Amended and Restated Employment Agreement between Executive and Company entered into as of May 28, 2018 (the “Prior Agreement”). Certain capitalized terms used in this Agreement are defined in Section 11.
Amendment #2 Cooperative Research and Development Agreement #12-1-00012Research and Development Agreement • February 25th, 2021 • Tracon Pharmaceuticals, Inc. • Biological products, (no disgnostic substances)
The purpose of this amendment is to change certain terms of the above-referenced Cooperative Research and Development Agreement (CRADA). These changes are reflected below, and except for these changes, all other provisions of the original CRADA remain in full force and effect. Two originals of this amendment are provided for execution; one is to remain with the National Cancer Institute and the other is to remain with the Collaborator.
